Do not take ALA (alpha-lipoic acid) for migraines- at least for now.
Posted on June 22 2022,
Alpha-Lipoic Acid or ALA is most commonly known for its use in patients with diabetic neuropathy.
In the most recent study evaluating ALA for migraines, it was found that "no significant changes were observed for NO levels and duration of migraine pains."
Moreover, ALA was found to reduce the lifespan of mice.
https://pubmed.ncbi.nlm.nih.gov/22785389/
Healthy mice treated long-term with ALA developed hepatic steatosis and liver injury. The effect of long-term ALA supplementation in humans is currently unknown and, therefore, it is possible that similar negative effects could be observed.
With the risk of shortening lifespan and causing injury, ALA is just not worth the risk especially with limited to no benefit.
Thu, Apr 24, 25
Clinical Predictors for Efficacy of Erenumab (Aimovig) for Migraine
Discover key predictors of Aimovig (erenumab) response in migraine patients. This REFORM study reveals which patients benefit most from CGRP therapy and why timing matters. Evidence-based insights for better treatment...
Read MoreWed, Apr 23, 25
Effectiveness and Tolerability of Atogepant (Qulipta) in the Prevention of Migraine
STAR study shows atogepant (Qulipta) effectively reduces migraine days by 56.6% in real-world clinical practice, even for patients with previous treatment failures. Learn about this breakthrough.
Read MoreWed, Apr 23, 25
Impact of Visual Stimulus Complexity on Associative Learning in Migraine Patients
Groundbreaking research reveals how migraine patients process visual information differently. This 2025 study found that migraine patients take longer to process simple visual stimuli compared to complex images, which is...
Read More